Skip to main content
SpringerLink
Log in
Book cover

Stroke Genetics pp 97–106Cite as

Monogenic Disorder: Fabry Disease

  • Chapter
  • First Online:

Abstract

Fabry disease is a rare inborn error of metabolism, which causes a number of neurological disorders including stroke. This chapter summarizes our current understanding of this condition at the molecular level and addresses treatment strategies.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   159.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   209.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Desnick RJ, Ioannou YA, Eng CM. α-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease, vol. 2. 8th ed. New York: McGraw-Hill; 2001. p. 3733–74.

    Google Scholar 

  2. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31–40.

    Article  PubMed  CAS  Google Scholar 

  3. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Invest. 2004;34:236–42.

    Article  PubMed  CAS  Google Scholar 

  4. Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007;28:1228–35.

    Article  PubMed  Google Scholar 

  5. Morgan SH, Rudge P, Smith SJ, et al. The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency) – investigation of symptomatic and presymptomatic patients. Q J Med. 1990;75:491–507.

    PubMed  CAS  Google Scholar 

  6. Luciano CA, Russell JW, Banerjee TK, et al. Physiological characterization of neuropathy in Fabry’s disease. Muscle Nerve. 2002;26:622–9.

    Article  PubMed  Google Scholar 

  7. Kocen RS, Thomas PK. Peripheral nerve involvement in Fabry’s disease. Arch Neurol. 1970;22:81–8.

    Article  PubMed  CAS  Google Scholar 

  8. Onishi A, Dyck PJ. Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia and posterior columns. Arch Neurol. 1974;31:120–7.

    Article  PubMed  CAS  Google Scholar 

  9. Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol. 1996;40:8–17.

    Article  PubMed  CAS  Google Scholar 

  10. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750–60.

    Article  PubMed  CAS  Google Scholar 

  11. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38:769–74.

    Article  PubMed  CAS  Google Scholar 

  12. Galanos J, Nicholls K, Grigg L, et al. Clinical features of Fabry disease in Australian patients. Intern Med J. 2002;32:575–84.

    Article  PubMed  CAS  Google Scholar 

  13. Sims K, Politei J, Banikazemi M, et al. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events. Natural history data from the Fabry Registry. Stroke. 2009;40:788–94.

    Article  PubMed  Google Scholar 

  14. Deegan PB, Baehner AF, Barba Romero MA, for the European FOS Investigators, et al. Natural history of Fabry disease in females in the Fabry outcome survey. J Med Genet. 2006;43:347–52.

    Article  PubMed  CAS  Google Scholar 

  15. Mehta A, Ginsberg L, for the FOS Investigators. Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr. 2005;94 Suppl 447:24–7.

    Article  CAS  Google Scholar 

  16. Ginsberg L, Manara R, Reinke J, et al. Characterisation of ischaemic stroke in Fabry disease: data from the international Fabry outcome survey. Eur J Neurol. 2008;15 Suppl 3:21–2.

    Google Scholar 

  17. Fellgiebel A, Müller MJ, Ginsberg L. CNS manifestations of Fabry’s disease. Lancet Neurol. 2006;5:791–5.

    Article  PubMed  Google Scholar 

  18. Ginsberg L, Manara R, Valentine AR, et al. Magnetic resonance imaging changes in Fabry disease. Acta Paediatr. 2006;95 Suppl 451:57–62.

    Article  Google Scholar 

  19. Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology. 1998;50:1746–9.

    Article  PubMed  CAS  Google Scholar 

  20. Fellgiebel A, Müller MJ, Mazanek M, et al. White matter lesion severity in male and female patients with Fabry disease. Neurology. 2005;65:600–2.

    Article  PubMed  CAS  Google Scholar 

  21. Cabrera-Salazar MA, O’Rourke E, Charria-Ortiz G, et al. Radiological evidence of early cerebral microvascular disease in young children with Fabry disease. J Pediatr. 2005;147:102–5.

    Article  PubMed  Google Scholar 

  22. Rolfs A, Böttcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366:1794–6.

    Article  PubMed  Google Scholar 

  23. Reisin RC, Romero C, Marchesoni C, et al. Brain MRI findings in patients with Fabry disease. J Neurol Sci. 2011;305:41–4.

    Article  PubMed  Google Scholar 

  24. Moore DF, Ye F, Schiffmann R, et al. Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol. 2003;24:1096–101.

    PubMed  Google Scholar 

  25. Takanashi J, Barkovich AJ, Dillon WP, et al. T1 Hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. AJNR Am J Neuroradiol. 2003;24:916–21.

    PubMed  Google Scholar 

  26. Garzuly F, Maródi L, Erdös M, et al. Megadolichobasilar anomaly with thrombosis in a family with Fabry’s disease and a novel mutation in the α-galactosidase A gene. Brain. 2005;128:2078–83.

    Article  PubMed  Google Scholar 

  27. Fellgiebel A, Keller I, Marin D, et al. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology. 2009;72:63–8.

    Article  PubMed  CAS  Google Scholar 

  28. Ritter M, Dittrich R, Droste DW. Microembolus detection in four patients with Fabry disease: further support for a primarily microangiopathic origin of early cerebrovascular symptoms. Eur Neurol. 2003;50:141–5.

    Article  PubMed  Google Scholar 

  29. Moore DF, Scott LT, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway deregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation. 2001;104:1506–12.

    Article  PubMed  CAS  Google Scholar 

  30. Hilz MJ, Kolodny EH, Brys M, et al. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol. 2004;251:564–70.

    Article  PubMed  Google Scholar 

  31. DeGraba T, Azhar S, Dignat-George F, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol. 2000;47:229–33.

    Article  PubMed  CAS  Google Scholar 

  32. Wozniak MA, Kittner SJ, Tuhrim S, et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke. 2010;41:78–81.

    Article  PubMed  Google Scholar 

  33. Baptista MV, Ferreira S, Pinho-E-Melo T, for the PORTuguese Young STROKE Investigators, et al. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study–screening genetic conditions in Portuguese young stroke patients. Stroke. 2010;41:431–6.

    Article  PubMed  CAS  Google Scholar 

  34. Brouns R, Thijs V, Eyskens F, for the BeFaS Investigators, et al. Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke. 2010;41:863–8.

    Article  PubMed  Google Scholar 

  35. Schiffmann R, Kopp JB, Austin 3rd HA, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743–9.

    Article  PubMed  CAS  Google Scholar 

  36. Eng CM, Guffon N, Wilcox WR, for the International Collaborative Fabry Disease Study Group, et al. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med. 2001;345:9–16.

    Article  PubMed  CAS  Google Scholar 

  37. Schiffmann R, Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 2003;28:703–10.

    Article  PubMed  CAS  Google Scholar 

  38. Hajioff D, Enever Y, Quiney R, et al. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis. 2003;26:787–94.

    Article  PubMed  CAS  Google Scholar 

  39. Mehta A, Beck M, Elliott P, for the Fabry Outcome Survey Investigators, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet. 2009;374:1986–96.

    Article  PubMed  CAS  Google Scholar 

  40. Jardim L, Vedolini L, Schwartz IVD, et al. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis. 2004;27:229–40.

    Article  PubMed  CAS  Google Scholar 

  41. Buechner S, Moretti M, Burlina AP, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry. 2008;79:1249–54.

    Article  PubMed  CAS  Google Scholar 

  42. Schiffmann R, Rapkiewicz A, Abu-Asab M, et al. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch. 2005;29:1–7.

    Google Scholar 

  43. Altarescu G, Moore DF, Schiffmann R. Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology. 2005;64:2148–50.

    Article  PubMed  CAS  Google Scholar 

  44. Albrecht J, Dellani PR, Müller MJ, et al. Voxel based analyses of diffusion tensor imaging in Fabry disease. J Neurol Neurosurg Psychiatry. 2007;78:964–9.

    Article  PubMed  CAS  Google Scholar 

  45. Hughes DA, Malmenas M, Deegan PB, et al. Fabry international prognostic index – a predictive severity score for Anderson-Fabry disease. J Med Genet. 2012;49:212–20.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University College London, Medical School, Royal Free Hospital, London, UK

    Lionel Ginsberg B.Sc., M.B.B.S., Ph.D., FRCP

Authors
  1. Lionel Ginsberg B.Sc., M.B.B.S., Ph.D., FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lionel Ginsberg B.Sc., M.B.B.S., Ph.D., FRCP .

Editor information

Editors and Affiliations

  1. Imperial College London & Hammersmith Ho, Fulham Palace Road, London, W6 8RF, United Kingdom

    Pankaj Sharma

  2. , Mayo Clinic Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, 32224, Florida, USA

    James F Meschia

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Ginsberg, L. (2013). Monogenic Disorder: Fabry Disease. In: Sharma, P., Meschia, J. (eds) Stroke Genetics. Springer, London. https://doi.org/10.1007/978-0-85729-209-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-209-4_7

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-208-7

  • Online ISBN: 978-0-85729-209-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation